The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Open accessAbstract
Summary Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients but does not eliminate leukemia stem cells (LSC), which remain a potential source of relapse. Here we investigated the ability of HDAC inhibitors (HDACi) to target CML stem cells. Treatment with HDACi combined with IM effectively induced apoptosis in quiescent CML progenitors resistant to elimination by IM alone, and eliminated CML stem cells capable of engrafting immunodeficient mice. In vivo administration of HDACi with IM markedly diminished LSC in a transgenic mouse model of CML. The interaction of IM and HDACi inhibited genes regulating hematopoietic stem cell maintenance and survival. HDACi treatment represents an effective strategy to target LSC in CML patients receiving tyrosine kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,051
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“Anticancer effects may also be related to modulation of the acetylation status of nonhistone proteins (Bolden et al., 2006).”
BackgroundShultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,728
Self-citationSawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Self-citationEmerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021
Transcription factor YY1: structure, function, and therapeutic implications in cancer biology
Gordon, S., Akopyan, G., Garban, H., & Bonavida, B. (2006) · Oncogene · doi:10.1038/sj.onc.1209080 · Cited by 756
Larochelle, A., Vormoor, J., Hanenberg, H., Wang, J. C. Y., Bhatia, M., Lapidot, T., Moritz, T., Murdoch, B., Xiao, X. L., Kato, I., et al. (1996) · Nature Medicine · doi:10.1038/nm1296-1329 · Cited by 726
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
Self-citationThe biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003) · Blood · doi:10.1182/blood-2002-09-2780 · Cited by 547
Self-citationRousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M., Maarek, O., Blanchet, O., Marit, G., Gluckman, E., Reiffers, J., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011239 · Cited by 538
Holyoake, T., Jiang, X., Eaves, C., & Eaves, A. (1999) · Blood · doi:10.1182/blood.v94.6.2056 · Cited by 515
Self-citationHistone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
HDAC inhibitors: Clinical update and mechanism-based potential
Glaser, K. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.04.007 · Cited by 348
Jørgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C., & Holyoake, T. L. (2007) · Blood · doi:10.1182/blood-2006-11-057521 · Cited by 306
Self-citationHematopoietic stem cell function and survival depend on c-Myc and N-Myc activity
Laurenti, E., Varnum-Finney, B., Wilson, A., Ferrero, I., Blanco-Bose, W. E., Ehninger, A., Knoepfler, P. S., Cheng, P.-F., MacDonald, H. R., Eisenman, R. N., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.09.005 · Cited by 305
Discontinuation of imatinib therapy after achieving a molecular response
Cortes, J., O'Brien, S., & Kantarjian, H. (2004) · Blood · doi:10.1182/blood-2004-04-1335 · Cited by 280
Nimmanapalli, R., Fuino, L., Bali, P., Gasparetto, M., Glozak, M. A., Tao, J., Moscinski, L. C., Smith, C. A., Wu, J., Jove, R., et al. (2003) · PubMed · Cited by 276
Holtz, M. S., Slovak, M. L., Zhang, F., Sawyers, C. L., Forman, S. J., & Bhatia, R. (2002) · Blood · doi:10.1182/blood.v99.10.3792 · Cited by 253
Self-citationBranford, Hughes, & Rudzki (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01749.x · Cited by 234
Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V., & Bhalla, K. (2003) · Blood · doi:10.1182/blood-2002-08-2675 · Cited by 222
Chu, S., Xu, H., Shah, N. P., Snyder, D. S., Forman, S. J., Sawyers, C. L., & Bhatia, R. (2005) · Blood · doi:10.1182/blood-2004-03-1114 · Cited by 209
Self-citationWang, J. C. Y., Lapidot, T., Cashman, J. D., Doedens, M., Addy, L., Sutherland, D. R., Nayar, R., Laraya, P., Minden, M., Keating, A., et al. (1998) · Blood · doi:10.1182/blood.v91.7.2406 · Cited by 190
Bhatia, R., McGlave, P., Dewald, G., Blazar, B., & Verfaillie, C. (1995) · Blood · doi:10.1182/blood.v85.12.3636.bloodjournal85123636 · Cited by 178
Self-citationChu, S., Holtz, M., Gupta, M., & Bhatia, R. (2004) · Blood · doi:10.1182/blood-2003-04-1271 · Cited by 163
Self-citationFunctional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
Jordanides, N. E., Jorgensen, H. G., Holyoake, T. L., & Mountford, J. C. (2006) · Blood · doi:10.1182/blood-2006-02-003145 · Cited by 158
Self-citationHoltz, M. S., Forman, S. J., & Bhatia, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403724 · Cited by 152
Self-citationFiskus, W. C., Pranpat, M., Bali, P., Balasis, M. E., Kumaraswamy, S., Boyapalle, S., Rocha, K., Wu, J., Giles, F. J., Manley, P. W., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4639 · Cited by 145
Bruserud, Ø., Stapnes, C., Ersvær, E., Gjertsen, B. T., & Ryningen, A. (2007) · Current Pharmaceutical Biotechnology · doi:10.2174/138920107783018417 · Cited by 141
Antioxidant and cytoprotective responses to redox stress
Mathers, J. E., Fraser, J. A., McMahon, M. J., Saunders, R. D. C., Hayes, J. D., & McLellan, L. I. (2004) · Biochemical Society Symposia · doi:10.1042/bss0710157 · Cited by 134
Copland, M., Pellicano, F., Richmond, L., Allan, E. K., Hamilton, A., Lee, F. Y., Weinmann, R. S., & Holyoake, T. L. (2007) · Blood · doi:10.1182/blood-2007-09-112573 · Cited by 131
Self-citationHistone deacetylase inhibitors specifically kill nonproliferating tumour cells
Burgess, A., Ruefli, A. A., Beamish, H., Warrener, R., Saunders, N. A., Johnstone, R. W., & Gabrielli, B. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207893 · Cited by 128
Koenig, H., Holtz, M. S., Modi, H., Manley, P. W., Holyoake, T. L., Forman, S. J., & Bhatia, R. (2008) · Leukemia · doi:10.1038/sj.leu.2405086 · Cited by 111
Self-citationKoenig, H., Holyoake, T. L., & Bhatia, R. (2007) · Blood · doi:10.1182/blood-2007-05-092056 · Cited by 108
Self-citationFiskus, W. C., Pranpat, M., Balasis, M. E., Bali, P., Estrella, V. C., Kumaraswamy, S., Rao, R., Rocha, K., Herger, B. E., Lee, F. Y., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0980 · Cited by 102
Drosophila E2F1 Has Context-Specific Pro- and Antiapoptotic Properties during Development
Moon, N.-S., Frolov, M. V., Kwon, E.-J., Stefano, L. D., Dimova, D. K., Morris, E. J., Taylor‐Harding, B., White, K., & Dyson, N. J. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.08.015 · Cited by 84
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
Jørgensen, H. G., Allan, E. K., Graham, S. M., Godden, J., Richmond, L., Elliott, M. A., Mountford, J. C., Eaves, C. J., & Holyoake, T. L. (2005) · Leukemia · doi:10.1038/sj.leu.2403785 · Cited by 70
Self-citationHuettner, C. S., Koschmieder, S., Iwasaki, H., Iwasaki-Arai, J., Radomska, H. S., Akashi, K., & Tenen, D. G. (2003) · Blood · doi:10.1182/blood-2003-03-0768 · Cited by 68
Self-citation
Cited by
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869
Stem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Metadata
- Authors
- Zhang, B., Strauss, A. C., Chu, S., Li, M., Ho, Y., Shiang, K.-D., Snyder, D. S., Huettner, C. S., Shultz, L., Holyoake, T., & Bhatia, R.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 17
- Issue
- 5
- Pages
- 427-442
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2004821524
- Cited by
- 256
- References
- 44
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.